GAPSS: the Global Anti-Phospholipid Syndrome Score

Current risk assessment for thrombosis and pregnancy loss in systemic lupus erythematosus lacks integration of multiple risk domains. Prior research has shown that antiphospholipid antibodies, cardiovascular risk factors, and autoimmune antibody profiles each contribute independently to adverse outcomes. However, no prior work had resolved how to combine these factors into a single predictive tool. This gap motivated researchers to explore whether a composite score could improve risk stratification. Existing models either focus on single biomarkers or exclude clinical treatment variables. The uncertainty around optimal risk factor weighting drove the need for a new scoring system. No prior work had demonstrated a validated quantitative approach integrating antiphospholipid status, conventional risk factors, and treatment data. This limitation hindered accurate prediction of clinical events in SLE patients. The absence of a standardized risk score for thrombosis and pregnancy loss in lupus patients created a clinical need for better prognostic tools.

The study aimed to develop and validate a new risk score called the Global Anti-Phospholipid Syndrome Score (GAPSS). This score combines independent risk factors for thrombosis and pregnancy loss in systemic lupus erythematosus patients. Researchers wanted to determine if a composite score could better predict clinical events than individual markers alone. The specific problem addressed was the lack of an integrated risk assessment tool for lupus patients. The motivation came from the need to improve clinical decision-making through better risk prediction. The study focused on combining antiphospholipid antibody status with cardiovascular and autoimmune markers. The goal was to create a tool that could guide treatment decisions in high-risk patients. The researchers sought to validate their approach in a real-world patient cohort.

The study used a cross-sectional design involving 211 SLE patients. Clinical data, cardiovascular risk factors, and antibody profiles were collected. Patients were randomly divided into two groups using a computer-generated list. In the first group (n=106), multivariate analysis identified risk factors for thrombosis and pregnancy loss. Each identified risk factor was assigned points based on β-regression coefficients. The scoring system was then validated in the second group (n=105). The relationship between GAPSS and clinical events was analyzed using statistical comparisons. Both groups showed similar patterns of higher scores in patients with clinical events.

Patients with thrombosis or pregnancy loss had significantly higher GAPSS scores than those without events. In the first group, GAPSS was 9.3 (4.8) compared to 5.3 (4) in those without events (P < 0.001). For thrombosis alone, scores were 9.6 (4.8) vs 4.9 (5) (P = 0.027). For pregnancy loss, scores were 7.3 (5) vs 3.9 (5.1) (P = 0.024). In the second group, GAPSS was 9.5 (5.6) for those with events vs 3.9 (4.1) (P < 0.001). Thrombosis scores were 9.5 (5.6) vs 4.8 (5.4) (P = 0.036). Pregnancy loss scores were 7.9 (3.3) vs 3.8 (5.4) (P = 0.037). These results suggest the score effectively differentiates high-risk patients.

The study proposes that the Global Anti-Phospholipid Syndrome Score (GAPSS) improves risk prediction for thrombosis and pregnancy loss in SLE patients. The authors suggest that combining antiphospholipid status, cardiovascular risk factors, and treatment data enhances clinical risk assessment. The score was validated in two independent patient groups with consistent results. The researchers suggest that higher GAPSS values correlate with increased likelihood of clinical events. They propose that this quantitative tool could guide treatment decisions in high-risk patients. The authors suggest that the score may be useful for monitoring lupus patients over time. They propose that further research could explore the score’s utility in predicting other outcomes. The study concludes that GAPSS represents a significant advance in risk stratification for SLE patients.